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ABSTRACT
Objective. This study was conducted to characterize the pharmacokinetics, including extent of accumulation, and
safety and tolerability of fentanyl following multiple doses of fentanyl buccal tablet (FBT) in healthy Japanese
volunteers.
Methods. Healthy Japanese adults received 10 successive doses of open-label FBT 400 mg at 6-hour intervals.
Naltrexone was given to minimize the opioid effects of fentanyl. FBT was placed above a molar tooth between the
gum and cheek. Peak serum fentanyl concentration (Cmax), time to Cmax (tmax), and area under the serum fentanyl
concentration-time curve from 0 to 6 hours (AUC0–6) were summarized using descriptive statistics. Accumulation
ratio was calculated as Cmax for dose 10/Cmax for dose 1, and was calculated similarly for AUC0–6.
Results. Fourteen volunteers (mean age 33 years) were enrolled, and 13 completed the study. After doses 1 and 10,
respectively, mean (SD) Cmax was 1.70 (0.49) ng/mL and 1.97 (0.42) ng/mL, AUC0–6 was 4.46 (1.14) ng·h/mL and
6.81 (0.90) ng·h/mL, and median (range) tmax was 50 (30–110) minutes and 30 (15–120) minutes. Following 10
successive doses, systemic exposure (AUC0–6) was 55% higher than after dose 1, and Cmax was 23% higher. Steady
state was achieved within 3 days of dosing at 6-hour intervals, i.e., prior to dose 10. The most frequent adverse events
(AEs) were somnolence (N = 9), decreased oxygen saturation (N = 4), headache (N = 3), application-site pain
(N = 8), application-site erythema (N = 6), and application-site reaction (N = 5). All AEs were mild or moderate.
Conclusions. Following administration of FBT at 6-hour intervals to healthy Japanese volunteers, at steady state,
fentanyl exposure was higher by 55% (AUC0–6) and 23% (Cmax) than after a single dose of FBT. Adverse events were
mild or moderate.
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Introduction
F
entanyl buccal tablet (FBT; FENTORA
®,
Cephalon, Inc., Frazer, PA, USA) is approved
for marketing by the US Food and Drug Admin-
istration for the management of breakthrough
pain in patients with cancer who are already
receiving and who are tolerant to around-the-
clock opioid therapy for their underlying persis-
tent cancer pain [1–3]. FBT employs OraVescent
®
technology to enhance the rate and extent of
absorption of fentanyl across the buccal mucosa
[4]. The pharmacokinetic proﬁle of FBT has been
examined in several studies, primarily involving
healthy white volunteers [5–9]. The current study
was conducted to support the submission of a new
drug application for FBT in Japan. The objectives
of this study were to characterize the pharmacoki-
netics of fentanyl, including the extent of accumu-
lation, and to assess the safety and tolerability of This study was sponsored by Cephalon, Inc., Frazer, PA.
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in healthy Japanese volunteers.
Methods
Study Population
Healthy, adult Japanese volunteers residing in the
United States who were aged 20 to 55 years, had
lived fewer than 10 years outside of Japan, and had
a body mass index of 17.6 to 29 kg/m
2 were eligible
for this study. Volunteers agreed to refrain from
using tobacco products throughout the study.
Women of childbearing potential were required to
practice abstinence or use a reliable form of con-
traception for 14 days prior to screening and
throughout the study.
Exclusion criteria included a history or presence
of clinically signiﬁcant concomitant disease,
including clinically signiﬁcant laboratory, electro-
cardiogram (ECG), or physical examination
results at screening; history or presence of alcohol-
ism or drug abuse; hypersensitivity or idiosyncratic
reaction to fentanyl or related compounds; history
of frequent or widespread bilateral canker sores or
current oral pathology; or participation in another
clinical study within the previous 30 days. Volun-
teers were also excluded if they had smoked >10
cigarettes per day within 3 months, taken prescrip-
tion medications within 14 days or over-the-
counter medications within 7 days, or used drugs
known to be strong inhibitors or strong inducers
of cytochrome P450 (CYP) enzymes within 10 and
30 days, respectively, prior to administration of the
ﬁrst dose of study drug. In addition, women were
excluded if they were pregnant or lactating.
Study Design
This study was conducted at a single center
(Radiant Research, Honolulu, HI). The protocol
was approved by the Quorum Review, Inc., Insti-
tutional Review Board. All volunteers provided
written informed consent.
Volunteers received 10 successive single doses
of open-label FBT 400 mg, administered at 6-hour
intervals. Because healthy volunteers are not
opioid tolerant, the volunteers in this study also
received oral naltrexone 50 mg (Barr Pharmaceu-
ticals, Inc., Pomona, NY) 15 hours and 3 hours
before the ﬁrst FBT dose, and every 12 hours after
the ﬁrst dose (for a total of 7 doses) to minimize
the opioid receptor–mediated effects of fentanyl.
Coadministration of naltrexone with fentanyl
would not be expected to affect the pharmacoki-
netics of fentanyl because fentanyl is a substrate of
CYP3A4 [10], and naltrexone is not an inhibitor or
inducer of CYP3A4 [11].
Volunteers self-administered FBT by placing a
single tablet buccally above a molar tooth and
allowing it to disintegrate for 10 minutes. If any
portion of the tablet remained after 10 minutes,
the volunteer gently massaged the adjacent cheek
area for 5 minutes, at which time study center
personnel visually inspected the volunteer’s mouth
to note whether tablet particles were present. (It
should be noted that massage is no longer recom-
mended in the prescribing information [2].) Any
remaining material was allowed to disintegrate.
Volunteers refrained from drinking any liquids
until complete disappearance of the tablet residue,
and remained seated for 2 hours following admin-
istration of each of the ﬁrst 3 FBT doses.
DwellTime Assessment
Buccal dwell time, the time elapsed between place-
ment of FBT and complete disappearance of tablet
residue, was veriﬁed visually and recorded by study
personnel.
Sample Collection
Venous blood samples (5 mL each) were collected
for determination of fentanyl serum concentra-
tions. Collection times were just before placement
of each dose and 3, 6, 9, 12, 15, 20, 25, 30, 40, 50,
60, 70, 80, 90, 100, and 110 minutes, and 2, 4, and
6 hours after placement of dose 1. Samples were
also collected 15, 30, 40, 50, 60, 70, 80, 90, 100,
and 110 minutes, and 2, 4, 6, 10, 12, 18, 24, and 32
hours after placement of dose 10.
Blood samples were kept at room temperature
until they fully clotted. They were then centri-
fuged at 2,500 revolutions per minute at 4°C for
15 minutes to separate the serum, which was
stored in polypropylene containers at or below
-20°C until assayed.
Analytical Methods
Fentanyl concentrations were quantitated in
serum samples using a validated assay for high
performance liquid chromatography with tandem
mass spectrometry (HPLC-MS/MS; PE Sciex API
3,000, API 365, and API III Plus with an ESI
interface). The analyte and internal standard (d5-
fentanyl) were extracted from serum under basic
conditions. Serum extracts were evaporated to
dryness and reconstituted before injection onto
the HPLC-MS/MS. Detection was accomplished
using multiple-reaction monitoring in positive ion
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5,000 pg/mL (0.01–5.0 ng/mL). The lower limit
of quantitation was set at 50 pg/mL (0.05 ng/mL),
and fentanyl concentrations below this level were
given a value of 0.0 in the computation of mean
concentration values. For quality control samples,
interbatch precision (% coefﬁcient of variation)
was 4.6% and accuracy ranged from 95.5% to
102.0%.
Pharmacokinetic Analysis
For doses 1 and 10, maximum serum fentanyl con-
centration (Cmax), time to Cmax (tmax), and area
under the serum fentanyl concentration-time
curve (AUC) from time 0 to 6 hours (AUC0–6) were
determined. Additional pharmacokinetic param-
eters determined for dose 10 included minimum
serum fentanyl concentration (Cmin), AUC from
time 0 to last quantiﬁable serum concentration
(AUC0–last), and AUC from time 0 extrapolated to
inﬁnity (AUC0–•). Trough concentrations (Ctrough)
were analyzed in blood samples obtained immedi-
ately preceding each dose. Cmax,C min, and tmax were
obtained by inspection. AUC0–6 was obtained by
linear trapezoidal summation from time 0 to 6
hours post dose, and AUC0–last was obtained by
linear trapezoidal summation from time 0 to the
last quantiﬁable concentration after the last dose.
AUC0–• was obtained as AUC0–last + Clast/lz, where
Clast is the last quantiﬁable serum fentanyl concen-
tration and lz is the terminal elimination rate con-
stant. The half-life (t 1
2) could not be calculated
after dose 1 because there were insufﬁcient analy-
sis time points, i.e., only up to 6 hours. The t 1
2and
lz were determined from the terminal phase of
the last dose administered. In addition, the accu-
mulation ratio was calculated as the AUC0–6 ratio
for dose 10 to dose 1 and as the Cmax ratio for dose
10 to dose 1. Pharmacokinetic parameters were
determined from concentration-time data using
noncompartmental methods with WinNonlin
®
Professional software Version 4.1 (Pharsight
Corporation, Mountain View, CA).
Safety andTolerability Assessments
Clinical laboratory tests, 12-lead ECG, and physi-
cal examinations including vital signs were per-
formed at screening and at study completion or
early termination. Serial vital signs were measured
before and through 6 hours after the ﬁrst tablet
placement, and prior to all blood sampling times.
Continuous pulse oximetry was conducted, though
not recorded, for the ﬁrst 4 hours post dose and
whenever the volunteers attempted to sleep during
the study in the clinic. In addition, the oral mucosa
was examined by the investigator 1 hour after
tablet placement; any abnormality or untoward or
uncomfortable sensations in the mouth were
recorded as adverse events (AEs). Other AEs
observed by study personnel or reported by volun-
teers also were recorded.
Statistical Analyses
Descriptive statistics were used to summarize the
calculated pharmacokinetic parameters. Unless
otherwise stated, statistical tests were 2-sided with
an a level of 0.05. The accumulation ratio was
calculated as AUC0–6 for dose 10/AUC0–6 for dose
1, and as Cmax for dose 10/Cmax for dose 1. To assess
the attainment of steady state, analysis of variance
(anova) was performed on the natural log of pre-
dose concentrations for dose 8, 9, and 10, as well as
the 6-hour post-dose concentration after the last
dose. Both the pharmacokinetic population and
safety population were deﬁned as all volunteers
who received FBT. It was planned that 14 subjects
would be enrolled such that, after dropouts, 10
subjects would complete the study. The planned
ﬁnal sample size of 10 subjects was not based on a
statistical power calculation.
Results
Study Population
Fourteen healthy Japanese adults (7 men, 7
women) aged 20 to 50 years were enrolled in the
study (Table 1) and were included in both the
pharmacokinetic and safety populations. One vol-
unteer was discontinued after the eighth FBT dose
because of AEs; thus, 13 volunteers completed the
study.
Pharmacokinetic Results
The serum fentanyl distribution/elimination
pattern was triphasic after dose 10 (Figure 1).
Pharmacokinetic parameters after dose 1 and dose
10 are presented in Table 2. Median tmax occurred
50 minutes after dose 1 and 30 minutes after dose
Table 1 Demographic variables
N = 14
Age, year (mean [SD]) 33 (8)
Sex, female (N [%]) 7 (50)
Weight, kg (mean [SD]) 57.0 (9.1)
Height, cm (mean [SD]) 163.9 (9.2)
Body mass index, kg/m
2 (mean [SD]) 21.2 (2.1)
SD = standard deviation.
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were higher after dose 10 than after dose 1. After
dose 10, the AUC0–last and AUC0–• values were
similar (Table 2). Accumulation of serum fentanyl
from dose 1 to dose 10 was shown by the calcu-
lated accumulation ratios for AUC0–6 (1.55) and
Cmax (1.23). The mean t 1
2after dose 10 was 10.29
hours (Table 2). Mean (SD) trough values after
dose 7, 8, and 9 were 0.71 (0.17), 0.68 (0.15), and
0.58 (0.12) ng/mL, respectively, and the mean
(SD) value at 6 hours after dose 10 was 0.62 (0.10)
ng/mL. Steady state was achieved within 3 days of
dosing at 6-hour intervals, i.e., prior to dose 10
(Table 3).
Buccal DwellTime
The recorded dwell time of FBT in the buccal
cavity ranged from 9 to 60 minutes.
Safety andTolerability
As stated previously, naltrexone was administered
to these healthy volunteers to minimize the opioid
Figure 1 Mean (standard error of the
mean) serum fentanyl concentrations
after administration of 1 dose and 10
doses of fentanyl buccal tablet 400 mg
at 6-hour intervals (inset shows the
ﬁrst 6 hours).
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Table 2 Pharmacokinetic parameters following
administration of 1 dose of fentanyl buccal tablet 400 mg
and 10 doses at 6-hour intervals
Parameter
Dose 1 Dose 10
(N = 14) (N = 13)
Mean (SD) Mean (SD)
Cmax (ng/mL) 1.70 (0.49) 1.97 (0.42)
tmax (min)* 50 (30, 110) 30 (15, 120)
AUC0–6 (ng·h/mL) 4.46 (1.14) 6.81 (0.90)
Accumulation ratio,
† Cmax NA 1.23 (0.53)
Accumulation ratio,
† AUC0–6 NA 1.55 (0.35)
AUC0–•(ng·h/mL) NA 16.09 (2.26)
AUC0–last (ng·h/mL) NA 14.41 (1.83)
Cmin (ng/mL) NA 0.58 (0.11)
lz (1/h) NA 0.07 (0.01)
t 1
2 (h) NA 10.29 (1.53)
*tmax is presented as the median (range).
†For multiple versus single dosing, calculated as Cmax dose 10/Cmax dose 1
and as AUC0–6 dose 10/AUC0–6 dose 1.
Cmax = maximum serum fentanyl concentration; tmax = time to Cmax;
AUC0–6 = area under the serum fentanyl concentration-time curve (AUC) from
time 0 to 6 hours; AUC0–• = AUC from time 0 to inﬁnity; AUC0–last = AUC from
time 0 to the time of the last quantiﬁable serum fentanyl concentration;
Cmin = minimum serum fentanyl concentration; NA = not applicable;
lz = terminal elimination rate constant; t 1
2 = elimination half-life.
Table 3 Statistical evaluation of steady state after buccal administration of fentanyl buccal tablet 400 mg every 6 hours
for 10 doses
Sample time N
Steady state P value*
Least squares mean
(ng/mL) Sample time effect vs. predose 9 vs. predose 10 vs. postdose
† 10
Predose 8 14 0.6877 0.0007 0.3293 0.0002 0.0057
Predose 9 13 0.6549 — — 0.0029 0.0604
Predose 10 13 0.5586 — — — 0.2162
Postdose 10
† 13 0.5947 — — — —
*Equivalence across listed samples was assumed if P  0.05.
†Sample taken 6 hours following dose 10.
Note: Pre-dose concentration analysis was performed with an ANOVA model, ln(concentration) = subject + sample time, where subject was a random effect and
sample time was a ﬁxed effect.
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1 AE, all of which were mild or moderate. No
serious AEs occurred during the study. One vol-
unteer was discontinued from the study after
administration of FBT dose 8 and naltrexone dose
6 because of nausea and vomiting considered by
the investigator to have been related to study drug.
The most frequently reported AEs (incidence
10% of volunteers) that were not related to the
application site of FBT were somnolence (N = 9
[64.3%]), decreased oxygen saturation (N = 4
[28.6%]), headache (N = 3 [21.4%]), fatigue
(N = 2 [14.3%]), nausea (N = 2 [14.3%]), and
venipuncture-site pain (N = 2 [14.3%]). The 4
instances of decreased oxygen saturation, which
were based on the clinical judgment of the inves-
tigator, were reported as mild and related to study
drug, and all resolved with no action taken. The
most frequently reported application-site AEs
(incidence 10% of volunteers) were pain (N = 8
[57.1%]), erythema (N = 6 [42.9%]), and unspeci-
ﬁed site reactions (N = 5 [35.7%]). In addition,
there was 1 occurrence of each of the following
application-site AEs: bleeding, irritation, ulcer,
and vesicles. The incidence of changes in the oral
mucosa increased in proportion to the number of
doses administered. There were no clinically sig-
niﬁcant changes in clinical laboratory test results,
vital sign values, ECG parameters, or physical
examination ﬁndings during this study.
Discussion
The primary objectives of this study were to char-
acterize the pharmacokinetics of fentanyl, includ-
ing its accumulation, and the safety and tolerability
following administration of FBT 400 mg every 6
hours for a total of 10 doses. Accumulation of
fentanyl was noted from doses 1 to 10, with sys-
temic exposure (AUC0–6) 55% higher and Cmax
23% higher after the tenth dose compared with
the ﬁrst dose. Steady state was reached within 3
days of dosing at 6-hour intervals, i.e., prior to
dose 10. Fentanyl was rapidly absorbed following
buccal administration of FBT 400 mg, with a
median tmax of approximately 50 minutes following
a single dose and 30 minutes after multiple doses.
Dwell time of FBT in the buccal mucosa varied
from 9 to 60 minutes; however, it has been shown
that the pharmacokinetic proﬁle of fentanyl is not
affected by the dwell time [12].
Fourteen volunteers had AEs, all of which were
mild or moderate, with no serious AEs. The most
common AEs not related to the application site of
FBT were generally consistent with those previ-
ously reported in healthy volunteers who received
FBT and naltrexone [5,6,8,13]. The 4 instances of
decreased oxygen saturation were reported as mild
and related to study drug, and all resolved with no
action taken. The frequency of changes in the oral
mucosa increased as the number of administered
doses increased; therefore, patients should alter-
nate dosing between the two sides of the mouth if
they have mucosal irritation.
Limitations of this study include the enrollment
of healthy volunteers, who may not represent a
patient population. In particular, safety and toler-
ability ﬁndings would not be expected to reﬂect
those in patients because the healthy volunteers in
this study were administered oral naltrexone to
minimize the opioid effects of fentanyl.
In conclusion, in healthy Japanese volunteers
who received FBT 400 mg every 6 hours for 10
doses, fentanyl steady state was achieved prior to
dose 10 (i.e., approximately 3 days of dosing at
6-hour intervals), and systemic exposure was 55%
(AUC0–6) and 23% (Cmax) higher at steady state
than after a single dose.
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